M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities.
Francesco Costa,Marco Valgimigli +1 more
TL;DR: A subgroup analysis from the DAPT (Dual Antiplatelet Therapy) trial in which the effect of an extended treatment with D APT beyond 1 year was investigated in patients presenting with or without myocardial infarction is reported.
Journal ArticleDOI
Рекомендации esc/eacts по реваскуляризации миокарда 2014
Stephan Windecker,Philippe Kolh,Fernando Alfonso,Jean-Philippe Collet,Jochen Cremer,Volkmar Falk,Gerasimos Filippatos,Christian W. Hamm,Stuart J. Head,Peter Jüni,A. Pieter Kappetein,Adnan Kastrati,Juhani Knuuti,Ulf Landmesser,Günther Laufer,Franz-Josef Neumann,Dimitrios J. Richter,Patrick Schauerte,Miguel Sousa Uva,Giulio G. Stefanini,David P. Taggart,Lucia Torracca,Marco Valgimigli,William Wijns,Adam Witkowski +24 more
Journal ArticleDOI
Application of the MADS classification system in a "mega mammoth" stent trial: Feasibility and preliminary clinical implications.
Athanasios Katsikis,Ply Chichareon,Rafael Cavalcante,Carlos Collet,Rodrigo Modolo,Yoshinobu Onuma,Goran Stankovic,Yves Louvard,Pascal Vranckx,Marco Valgimigli,Stephan Windecker,Patrick W. Serruys +11 more
TL;DR: This work attempted to test the feasibility of application of the MADS classification system in the largest stent trial to date and evaluate the preliminary clinical implications of this approach.
Journal ArticleDOI
Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure.
Roberto Galea,Federico De Marco,Adel Aminian,Nicolas Meneveau,Frederic Anselme,Christoph Gräni,Adrian Thomas Huber,Emmanuel Teiger,Xavier Iriart,Marco Angelillis,Nicolas Brugger,Alessandro Spirito,Noé Corpataux,Anna Franzone,Pascal Vranckx,Urs Fischer,Giovanni Pedrazzini,Francesco Bedogni,Stephan Windecker,Lorenz Räber,Marco Valgimigli +20 more
TL;DR: In this paper, the authors compared Amulet and Watchman/FLX with respect to the prevalence of post-procedural leak as assessed with cardiac computed tomography angiography (CCTA) at 45 days and 13 months.
Journal ArticleDOI
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).
Chun Chin Chang,Ernest Spitzer,Ply Chichareon,Kuniaki Takahashi,Rodrigo Modolo,Norihiro Kogame,Mariusz Tomaniak,Hidenori Komiyama,Sing-Chien Yap,Stephen P. Hoole,Tommaso Gori,Azfar Zaman,Bernhard Frey,Rui Cruz Ferreira,Olivier F. Bertrand,Tian Hai Koh,Amanda G. M. R. Sousa,Aris Moschovitis,Robert-Jan van Geuns,Philippe Gabriel Steg,Christian W. Hamm,Peter Jüni,Pascal Vranckx,Marco Valgimigli,Stephan Windecker,Patrick W. Serruys,Osama Ibrahim Ibrahim Soliman,Yoshinobu Onuma +27 more
TL;DR: The prevalence of silent MI in an all-comers population undergoing PCI in this large-scale randomized trial, which randomized 15,991 patients who underwent PCI to 2 antiplatelet treatment strategies, is documented.